NASDAQ:INMB INmune Bio (INMB) Stock Price, News & Analysis $2.00 -0.16 (-7.41%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$2.01 +0.01 (+0.45%) As of 04:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About INmune Bio Stock (NASDAQ:INMB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get INmune Bio alerts:Sign Up Key Stats Today's Range$1.99▼$2.1850-Day Range$1.62▼$2.5152-Week Range$1.09▼$2.60Volume487,555 shsAverage Volume343,896 shsMarket Capitalization$55.51 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingModerate Buy Company Overview INmune Bio, Inc. is a clinical-stage biotechnology company developing treatments that target the innate immune system. The company focuses on therapies designed to address chronic inflammation and immune dysfunction associated with cancer, neurodegenerative diseases and other serious medical conditions. Its lead technology, XPro, is an engineered form of tumor necrosis factor (TNF) designed to selectively neutralize soluble TNF while preserving transmembrane TNF activity. INmune Bio is studying XPro in conditions involving neuroinflammation, including Alzheimer’s disease and treatment-resistant depression. The company’s second platform, INKmune, is designed to activate a patient’s natural killer cells and is being developed as an oncology immunotherapy. INmune Bio was founded in 2015 and is headquartered in Boca Raton, Florida. Its clinical development activities have included studies in the United States and other regions. The company is led by Chief Executive Officer and co-founder R. J. Tesi, M.D., who has a background in medicine, oncology and biotechnology.AI Generated. May Contain Errors. Read More INmune Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreINMB MarketRank™: INmune Bio scored higher than 6% of companies evaluated by MarketBeat, and ranked 872nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingModerate Buy Consensus RatingINmune Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageINmune Bio has only been the subject of 1 research reports in the past 90 days.Read more about INmune Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of INmune Bio is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of INmune Bio is -2.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioINmune Bio has a P/B Ratio of 2.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about INmune Bio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.01% of the float of INmune Bio has been sold short.Short Interest Ratio / Days to CoverINmune Bio has a short interest ratio ("days to cover") of 6.26.Change versus previous monthShort interest in INmune Bio has recently increased by 3.89%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldINmune Bio does not currently pay a dividend.Dividend GrowthINmune Bio does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest3 people have searched for INMB on MarketBeat in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, INmune Bio insiders have not sold or bought any company stock.Percentage Held by Insiders21.40% of the stock of INmune Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions12.72% of the stock of INmune Bio is held by institutions.Read more about INmune Bio's insider trading history. Receive INMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INMB Stock News HeadlinesINmune Bio Adds Rare Disease, Biopharma Executives Duane Clark And James Sapirstein To BoardSeptember 15, 2026 | rttnews.comINmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to BoardSeptember 14, 2026 | globenewswire.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under. | Paradigm Press (Ad)INmune Bio to Present at the H.C. Wainwright Global Investment ConferenceSeptember 9, 2026 | globenewswire.comINmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory AlignmentAugust 28, 2026 | seekingalpha.comINmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory FilingsAugust 26, 2026 | globenewswire.comINmune Bio targets Ebstrocel U.K. MAA by end of Q3 or early Q4 2026 while outlining $1M-$1.5M monthly burnAugust 7, 2026 | seekingalpha.comINmune Bio (INMB) Q2 2026 Earnings Call TranscriptAugust 7, 2026 | finance.yahoo.comSee More Headlines INMB Stock Analysis - Frequently Asked Questions How have INMB shares performed this year? INmune Bio's stock was trading at $1.56 at the beginning of the year. Since then, INMB stock has increased by 28.2% and is now trading at $2.00. How were INmune Bio's earnings last quarter? INmune Bio, Inc. (NASDAQ:INMB) posted its earnings results on Thursday, August, 6th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.16. Read the conference call transcript. When did INmune Bio IPO? INmune Bio (INMB) raised $20 million in an initial public offering on the week of February 4th 2019. The company issued 2,500,000 shares at $8.00 per share. Who are INmune Bio's major shareholders? Top institutional investors of INmune Bio include BlackRock Inc. (1.17%), Ieq Capital LLC (0.30%), GSA Capital Partners LLP (0.31%) and Focus Partners Advisor Solutions LLC (0.16%). Insiders that own company stock include Raymond Joseph Tesi, David J Moss and Scott Juda. View institutional ownership trends. How do I buy shares of INmune Bio? Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of INmune Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that INmune Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Netflix (NFLX). Company Calendar Last Earnings8/06/2026Today9/23/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 INMB's financial health is in the Green zone, according to TradeSmith. INMB has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:INMB CIK1711754 Webwww.inmunebio.com Phone(858) 964-3720FaxN/AEmployees21Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.93 million Net MarginsN/A Pretax Margin-91,866.00% Return on Equity-82.87% Return on Assets-62.23% Debt Debt-to-Equity RatioN/A Current Ratio4.04 Quick Ratio4.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.88 per share Price / Book2.27Miscellaneous Outstanding Shares27,754,000Free Float21,815,000Market Cap$55.51 million OptionableOptionable Beta0.93 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:INMB) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredMy next big call (under $1)While the Senate was failing to pass the CLARITY Act, the SEC already had its own crypto framework on the tabl...Crypto 101 Media | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
